Journal of Internal Medicine最新文献

{"title":"Significance of clinical-immunological patterns and diagnostic yield of biopsies in microscopic polyangiitis and granulomatosis with polyangiitis","authors":"João Fernandes-Serodio,&nbsp;Sergio Prieto-González,&nbsp;Georgina Espígol-Frigolé,&nbsp;Roberto Ríos-Garcés,&nbsp;Verónica Gómez-Caverzaschi,&nbsp;Olga Araújo,&nbsp;Gerard Espinosa,&nbsp;Raül Jordà-Sánchez,&nbsp;Marco A. Alba,&nbsp;Luis Quintana,&nbsp;Miquel Blasco,&nbsp;Elena Guillen,&nbsp;Odette Viñas,&nbsp;Estíbaliz Ruiz-Ortiz,&nbsp;Laura Pelegrín,&nbsp;Maite Sainz de la Maza,&nbsp;Bernardo Sánchez-Dalmau,&nbsp;Adriana García-Herrera,&nbsp;Manel Solé,&nbsp;Paola Castillo,&nbsp;Iban Aldecoa,&nbsp;María D. Cano,&nbsp;Jacobo Sellarés,&nbsp;Fernanda Hernández-González,&nbsp;Carlos Agustí,&nbsp;Carmen M. Lucena,&nbsp;Antonio López-Rueda,&nbsp;Marcelo Sánchez,&nbsp;Mariana Benegas,&nbsp;Sebastián Capurro,&nbsp;Raimon Sanmartí,&nbsp;Josep M. Grau,&nbsp;Isabel Vilaseca,&nbsp;Isam Alobid,&nbsp;Maria C. Cid,&nbsp;José Hernández-Rodríguez","doi":"10.1111/joim.13777","DOIUrl":"10.1111/joim.13777","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are the two major antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterize a homogenous AAV cohort and to assess the impact of clinicopathological profiles and ANCA serotypes on clinical presentation and prognosis. Clinical differences in GPA patients according to ANCA serotype and the diagnostic yield for vasculitis of biopsies in different territories were also investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This retrospective study (2000–2021) included 152 patients with AAV (77 MPA/75 GPA). MPA patients (96.1% myeloperoxidase [MPO]–ANCA and 2.6% proteinase 3 [PR3]–ANCA) presented more often with weight loss, myalgia, renal involvement, interstitial lung disease (ILD), cutaneous purpura, and peripheral nerve involvement. Patients with GPA (44% PR3–ANCA, 33.3% MPO, and 22.7% negative/atypical ANCA) presented more commonly with ear, nose, and throat and eye/orbital manifestations, more relapses, and higher survival than patients with MPA. GPA was the only independent risk factor for relapse. Poor survival predictors were older age at diagnosis and peripheral nerve involvement. ANCA serotypes differentiated clinical features in a lesser degree than clinical phenotypes. A mean of 1.5 biopsies were performed in 93.4% of patients in different territories. Overall, vasculitis was identified in 80.3% (97.3% in MPA and 61.8% in GPA) of patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The identification of GPA presentations associated with MPO–ANCA and awareness of risk factors for relapse and mortality are important to guide proper therapeutic strategies in AAV patients. Biopsies of different affected territories should be pursued in difficult-to-diagnose patients based on their significant diagnostic yield.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"651-667"},"PeriodicalIF":11.1,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Focus on senescence: Clinical significance and practical applications","authors":"Virginia Boccardi,&nbsp;Miranda Ethel Orr,&nbsp;M. Cristina Polidori,&nbsp;Carmelinda Ruggiero,&nbsp;Patrizia Mecocci","doi":"10.1111/joim.13775","DOIUrl":"10.1111/joim.13775","url":null,"abstract":"<p>The older population is increasing worldwide, and life expectancy is continuously rising, predominantly thanks to medical and technological progress. Healthspan refers to the number of years an individual can live in good health. From a gerontological viewpoint, the mission is to extend the life spent in good health, promoting well-being and minimizing the impact of aging-related diseases to slow the aging process. Biologically, aging is a malleable process characterized by an intra- and inter-individual heterogeneous and dynamic balance between accumulating damage and repair mechanisms. Cellular senescence is a key component of this process, with senescent cells accumulating in different tissues and organs, leading to aging and age-related disease susceptibility over time. Removing senescent cells from the body or slowing down the burden rate has been proposed as an efficient way to reduce age-dependent deterioration. In animal models, senotherapeutic molecules can extend life expectancy and lifespan by either senolytic or senomorphic activity. Much research shows that dietary and physical activity-driven lifestyle interventions protect against senescence. This narrative review aims to summarize the current knowledge on targeting senescent cells to reduce the risk of age-related disease in animal models and their translational potential for humans. We focused on studies that have examined the potential role of senotherapeutics in slowing the aging process and modifying age-related disease burdens. The review concludes with a general discussion of the mechanisms underlying this unique trajectory and its implications for future research.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"599-619"},"PeriodicalIF":11.1,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13775","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dynamics of B-cell reconstitution post allogeneic hematopoietic stem cell transplantation: A real-world study","authors":"Guangyu Zhou,&nbsp;Qian Zhan,&nbsp;Lingle Huang,&nbsp;Xi Dou,&nbsp;Jin Cui,&nbsp;Lin Xiang,&nbsp;Yuhong Qi,&nbsp;Sicen Wu,&nbsp;Lin Liu,&nbsp;Qing Xiao,&nbsp;Jianbin Chen,&nbsp;Xiaoqiong Tang,&nbsp;Hongbin Zhang,&nbsp;Xin Wang,&nbsp;Xiaohua Luo,&nbsp;Guosheng Ren,&nbsp;Zesong Yang,&nbsp;Lanxiang Liu,&nbsp;Xinyu Yan,&nbsp;Qin Luo,&nbsp;Caixia Pei,&nbsp;Yulian Dai,&nbsp;Yu Zhu,&nbsp;Hao Zhou,&nbsp;Guilin Ren,&nbsp;Li Wang","doi":"10.1111/joim.13776","DOIUrl":"10.1111/joim.13776","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for preventing infections and relapse and enhancing graft-versus-tumor effects. B cells play an important role in humoral immunity and immune regulation, but their reconstitution after allo-HSCT has not been well studied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we analyzed the dynamics of B cells in 252 patients who underwent allo-HSCT for 2 years and assessed the impact of factors on B-cell reconstitution and their correlations with survival outcomes, as well as the development stages of B cells in the bone marrow and the subsets in the peripheral blood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that the B-cell reconstitution in the bone marrow was consistent with the peripheral blood (<i>p</i> = 0.232). B-cell reconstitution was delayed by the male gender, age &gt;50, older donor age, the occurrence of chronic and acute graft-versus-host disease, and the infections of fungi and cytomegalovirus. The survival analysis revealed that patients with lower B cells had higher risks of death and relapse. More importantly, we used propensity score matching to obtain the conclusion that post-1-year B-cell reconstitution is better in females. Meanwhile, using mediation analysis, we proposed the age-B cells-survival axis and found that B-cell reconstitution at month 12 posttransplant mediated the effect of age on patient survival (<i>p</i> = 0.013). We also found that younger patients showed more immature B cells in the bone marrow after transplantation (<i>p</i> = 0.037).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings provide valuable insights for optimizing the management of B-cell reconstitution and improving the efficacy and safety of allo-HSCT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"634-650"},"PeriodicalIF":11.1,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140026939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human health and the health of Planet Earth go together","authors":"Josep M. Antó","doi":"10.1111/joim.13774","DOIUrl":"10.1111/joim.13774","url":null,"abstract":"<p>The emergence of the planetary health approach was highlighted by the report of The Rockefeller Foundation-Lancet Commission on Planetary Health in 2015 and changed how we comprehend human well-being. The report advocates integrating the health of other living beings and Earth's natural systems as intrinsic components of human health. Drawing on over three decades of experience in respiratory epidemiology and environmental health, this article outlines how my perspective on human health underwent a transformative shift upon reading the abovementioned report. The planetary health approach offers a lens through which human health issues and potential solutions can be understood within the context of the Anthropocene. It addresses the pressing existential challenges arising from humanity's transgression of planetary limits. Embracing the planetary health paradigm within the field of health sciences can catalyze transformative changes essential for cultivating a sustainable and equitable future.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"695-706"},"PeriodicalIF":11.1,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13774","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139988792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infertility treatment is associated with increased risk of postpartum hospitalization due to heart disease","authors":"Rei Yamada,&nbsp;Devika Sachdev,&nbsp;Rachel Lee,&nbsp;Mark V. Sauer,&nbsp;Cande V. Ananth","doi":"10.1111/joim.13773","DOIUrl":"10.1111/joim.13773","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cardiovascular disease is a major cause of maternal mortality, but the extent to which infertility treatment is implicated in heart disease remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the association between infertility treatment and postpartum heart disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We designed a retrospective cohort study of patients who delivered in the United States between 2010 and 2018. The primary outcome was hospitalization within 12-month post-delivery due to heart disease (including ischemic heart disease, atherosclerotic heart disease, cardiomyopathy, hypertensive disease, heart failure, and cardiac dysrhythmias). We estimated the rate difference (RD) of hospitalizations among patients who conceived with infertility treatment and those who conceived spontaneously. Associations were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs), derived from Cox proportional hazards regression after adjustment for potential confounders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Infertility treatment was recorded in 0.9% (<i>n</i> = 287,813) of 31,339,991 deliveries. Rates of heart disease hospitalizations with infertility treatment and with spontaneous conception were 550 and 355 per 100,000, respectively (RD 195, 95% CI: 143–247; adjusted HR 1.99, 95% CI: 1.80–2.20). The most important increase in risk was observed for hypertensive disease (adjusted HR 2.16, 95% CI: 1.92–2.42). This increased risk was apparent as early as 30-day post-delivery (HR 1.61, 95% CI: 1.39–1.86), with progressively increasing risk up to a year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although the absolute risk of postpartum heart disease hospitalization is low, infertility treatment is associated with an increased risk, especially for hypertensive disease. These findings highlight the importance of timely postpartum follow-ups in patients who received infertility treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"668-678"},"PeriodicalIF":11.1,"publicationDate":"2024-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13773","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139970323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials","authors":"Takahito Doi,&nbsp;Anne Langsted,&nbsp;Børge G. Nordestgaard","doi":"10.1111/joim.13771","DOIUrl":"10.1111/joim.13771","url":null,"abstract":"","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"707-710"},"PeriodicalIF":11.1,"publicationDate":"2024-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139720976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment","authors":"Magnus Ingelman-Sundberg,&nbsp;Munir Pirmohamed","doi":"10.1111/joim.13772","DOIUrl":"10.1111/joim.13772","url":null,"abstract":"<p>Pharmacogenomics is the examination of how genetic variation influences drug metabolism and response, in terms of both efficacy and safety. In cardiovascular disease, patient-specific diplotypes determine phenotypes, thereby influencing the efficacy and safety of drug treatments, including statins, antiarrhythmics, anticoagulants and antiplatelets. Notably, polymorphisms in key genes, such as <i>CYP2C9, CYP2C19, VKORC1</i> and <i>SLCO1B1</i>, significantly impact the outcomes of treatment with clopidogrel, warfarin and simvastatin. Furthermore, the <i>CYP2C19</i> polymorphism influences the pharmacokinetics and safety of the novel hypertrophic cardiomyopathy inhibitor, mavacamten. In this review, we critically assess the clinical application of pharmacogenomics in cardiovascular disease and delineate present and future utilization of pharmacogenomics. This includes insights into identifying missing heritability, the integration of whole genome sequencing and the application of polygenic risk scores to enhance the precision of personalized drug therapy. Our discussion encompasses health economic analyses that underscore the cost benefits associated with pre-emptive genotyping for warfarin and clopidogrel treatments, albeit acknowledging the need for further research in this area. In summary, we contend that cardiovascular pharmacogenomic analyses are underpinned by a wealth of evidence, and implementation is already occurring for some of these gene–drug pairs, but as with any area of medicine, we need to continually gather more information to optimize the use of pharmacogenomics in clinical practice.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"583-598"},"PeriodicalIF":11.1,"publicationDate":"2024-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13772","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139720977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roxadustat reduces left ventricular mass index compared to rHuEPO in haemodialysis patients in a randomized controlled trial","authors":"Wei Tan,&nbsp;Xiang Wang,&nbsp;Yudong Sun,&nbsp;Xiaohui Wang,&nbsp;Jin He,&nbsp;Ling Zhong,&nbsp;Xianhong Jiang,&nbsp;Yan Sun,&nbsp;En Tian,&nbsp;Zhuoying Li,&nbsp;Liangping He,&nbsp;Ying Hao,&nbsp;Bin Tang,&nbsp;Wei Hua,&nbsp;Xiangyu Ma,&nbsp;Jurong Yang","doi":"10.1111/joim.13770","DOIUrl":"10.1111/joim.13770","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Left ventricular hypertrophy (LVH) is highly prevalent in haemodialysis (HD) patients and is associated with an increased risk of death. Roxadustat and recombinant human erythropoietin (rHuEPO, abbreviated as EPO) are the main treatment strategies for renal anaemia in HD patients, but it has not been clear whether there is a difference in their effect on LVH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this multi-centre, prospective, randomized trial of 12-month duration, study participants were randomized in a 1:1 ratio to the roxadustat group or the EPO group. The doses of both treatment regimens were adjusted so that the patients had a haemoglobin level of 10.0–12.0 g per dL. The primary study endpoint was the change from baseline to 12 months in the left ventricular mass index (LVMI, g/m²) measured by echocardiography.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 114 patients were enrolled. The mean age was 50 years, and the median dialysis duration was 33 months. Sixty-one patients were men, and 24 were diabetic. LVMI decreased from 116.18 ± 27.84 to 110.70 ± 25.74 g/m² in the roxadustat group. However, it increased from 109.35 ± 23.41 to 114.99 ± 28.46 g/m² in the EPO group, with a significant difference in the change in LVMI between the two groups [−5.48 (−11.60 to 0.65) vs. 5.65 (0.74 to 10.55), <i>p</i> &lt; 0.05]. Changes in left ventricular mass, end-diastolic volume and 6-min walk test seemed superior in the roxadustat group. There were no significant differences in other cardiac geometry, biochemical parameters and major adverse cardiovascular events between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared to EPO, roxadustat is more helpful in the regression of LVH in HD patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 5","pages":"620-633"},"PeriodicalIF":11.1,"publicationDate":"2024-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139720978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment to external editors","authors":"","doi":"10.1111/joim.13769","DOIUrl":"10.1111/joim.13769","url":null,"abstract":"<p>The <i>Journal of Internal Medicine</i> acknowledges the valuable contribution of the five individuals who in 2023 acted as external editors to make manuscript decisions when there was an internal conflict of interest.</p><p>The Editors</p><p>Asplund, Kjell</p><p>Borén, Jan</p><p>Cederholm, Tommy</p><p>de Faire, Ulf</p><p>Wiklund, Olov</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 3","pages":"383"},"PeriodicalIF":11.1,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13769","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139670930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment to reviewers","authors":"","doi":"10.1111/joim.13768","DOIUrl":"10.1111/joim.13768","url":null,"abstract":"&lt;p&gt;The &lt;i&gt;Journal of Internal Medicine&lt;/i&gt; acknowledges the valuable contribution of the close to 350 reviewers who in 2023 helped in the scientific evaluation of manuscripts submitted to the journal. In addition to our authors and editorial board, these individuals from all over the world have helped the journal in its goal of becoming a high-ranking international publication.&lt;/p&gt;&lt;p&gt;The Editors&lt;/p&gt;&lt;p&gt;Aavitsland, Preben, &lt;i&gt;Norway&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Achim, Alexandru, &lt;i&gt;Switzerland&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Agarwal, Rajiv, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Al-Samkari, Hanny, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Amorim, Fabio Ferreira, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Anderson, Mark, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Anjum, Mariam, &lt;i&gt;Norway&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Antovic, Aleksandra, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Arafa, Ahmed, &lt;i&gt;Japan&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Armanini, Decio, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Aspberg, Sara, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Asplund, Kjell, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Baatrup, Gunnar, &lt;i&gt;Denmark&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bancos, Irina, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bantel, Heike, &lt;i&gt;Germany&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Barany, Peter, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Barchetta, Ilaria, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Barone, Biagio, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bayry, Jagadeesh, &lt;i&gt;France&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bengtsson, Bonnie, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bensing, Sophie, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Berentsen, Sigbjorn, &lt;i&gt;Norway&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Berge, Trygve, &lt;i&gt;Norway&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bergman, Frida, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bermejo-Martin, Jesus F, &lt;i&gt;Spain&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bernatsky, Sasha, &lt;i&gt;Canada&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Berti, Alvise, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Beuers, Ulrich, &lt;i&gt;the Netherlands&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Biondi, Bernadette, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bishop, David, &lt;i&gt;South Africa&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bishop, Nicholas, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bjerrum, Ole, &lt;i&gt;Denmark&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bokarewa, Maria, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bond, Carmel, &lt;i&gt;United Kingdom&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Boraska, Perica Vesna, &lt;i&gt;Croatia&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Borén, Jan, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Borgquist, Rasmus, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Boriani, Giuseppe, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Boström, Anne-Marie, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bottai, Matteo, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Boyle, Patrick, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Brandt, Eric, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bredin, Cecilia, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Brewster, Luke, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Brismar, Torkel, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Brown, Kimberly, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bruchfeld, Annette, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Bruchfeld, Judith, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Calderón-Larrañaga, Amaia, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Calissendorff, Jan, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Caramori, Gaetano, &lt;i&gt;Italy&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Castillo, Diego, &lt;i&gt;Spain&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Castro-Cabezas, Manuel, &lt;i&gt;the Netherlands&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chamberlain, Alanna, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chantzichristos, Dimitrios, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chapman, John, &lt;i&gt;France&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chaudhuri, Nazia, &lt;i&gt;United Kingdom&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chen, Frederick, &lt;i&gt;United Kingdom&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chen, Yu-Ming, &lt;i&gt;China&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chizolini, Carlo, &lt;i&gt;Switzerland&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Cho, Kyu Yong, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Chong, Ka Chun, &lt;i&gt;Hong Kong&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Christensson, Anders, &lt;i&gt;Sweden&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Cífková, Renata, &lt;i&gt;Czech Republic&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Clanton, Thomas, &lt;i&gt;United States&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Coll","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"295 3","pages":"379-382"},"PeriodicalIF":11.1,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13768","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139561703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}